A novel cancer drug developed by scientists at Wake Forest School of Medicine has successfully completed its Phase I clinical trial. The therapeutic, a unique approach to fighting cancer, aims to shut down or limit the activity of a cancer cell’s mitochondria – the “powerhouse” of the cell.
This type of treatment is effective because mitochondria function differently in healthy cells than in cancer cells. Timothy Pardee, MD, PhD, assistant professor of hematology and oncology, explains, “This is the first drug to inhibit mitochondria in this way and if it proves effective in further clinical trials, it will open up a whole new approach to fighting cancer.”
Read the full release to learn more about the clinical trial.